Small-molecule inhibitors of anti-apoptotic Bcl-2 proteins and BH3 mimetic peptides are promising anticancer agents. A recent study identifies a Nur77-based peptide that converts anti-apoptotic Bcl-2 proteins into pro-apoptotic molecules, providing another potential cancer therapeutic strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gavathiotis, E. et al. Nature 455, 1076–1081 (2008).
Oltersdorf, T. et al. Nature 435, 677–681 (2005).
Cheng, E.H. et al. Science 278, 1966–1968 (1997).
Clem, R.J. et al. Proc. Natl. Acad. Sci. USA 95, 554–559 (1998).
Kolluri, S.K. et al. Cancer Cell 14, 285–298 (2008).
Thompson, J. & Winoto, A. J. Exp. Med. 205, 1029–1036 (2008).
Hickman, J.A., Hardwick, J.M., Kaczmarek, L.K. & Jonas, E.A. J. Neurophysiol. 99, 1515–1522 (2008).
Krajewska, M. et al. Clin. Cancer Res. 14, 3011–3021 (2008).
Yip, K.W. et al. J. Biomol. Screen. 13, 665–673 (2008).
Luciano, F. et al. Blood 109, 3849–3855 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Qi, B., Hardwick, J. Bcl-2 turns deadly. Nat Chem Biol 4, 722–723 (2008). https://doi.org/10.1038/nchembio1208-722
Issue Date:
DOI: https://doi.org/10.1038/nchembio1208-722